Advanced search
Publication Cover
Acta Cardiologica Volume 74, 2019 - Issue 5
Submit an article Journal homepage
205
Views
18
CrossRef citations to date
0
Altmetric
Original Scientific Paper

Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients

Chirik Wah LauDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; View further author information
,
Pieter MartensDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; ;Doctoral School for Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium; Correspondence[email protected]
View further author information
,
Seppe LambeetsDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; View further author information
,
Matthias DupontDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; View further author information
&
Wilfried MullensDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; ;Faculty of Medicine and Life Sciences, Biomedical Research Institute, Hasselt University, Diepenbeek, BelgiumView further author information
Pages 405-412 | Received 22 Jul 2018, Accepted 04 Sep 2018, Published online: 25 Nov 2018

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Yusuf Ziya Şener, Metin Okşul & Ertugrul Çağri Bölek. (2021) Iron deficiency and heart failure. Acta Cardiologica 76:1, pages 107-107.
Read now
Gabriella Malfatto, Silvia Ravaro, Sergio Caravita, Claudia Baratto, Antonio Sorropago, Alessia Giglio, Michele Tomaselli, Gianfranco Parati & Alessandra Villani. (2020) Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test. Acta Cardiologica 75:8, pages 732-736.
Read now
Marc J. Claeys, Michel De Pauw, Peter Geelen, Patrizio Lancellotti & Luc Pierard. (2020) Review article: the best of 2018. Acta Cardiologica 75:5, pages 383-387.
Read now

Articles from other publishers (15)

Ina Volis, Maria Postnikov, Anat Reiner-Benaim, Yaron Hellman & Erez Marcusohn. (2024) Effect of angiotensin receptor neprilysin inhibitor on physical activity in patients with heart failure with reduced ejection fraction, monitored by implantable electronic device home monitoring. Journal of Cardiovascular Medicine 25:3, pages 193-199.
Crossref
Massimo Mapelli, Irene Mattavelli, Stefania Paolillo, Elisabetta Salvioni, Damiano Magrì, Arianna Galotta, Fabiana De Martino, Valentina Mantegazza, Carlo Vignati, Immacolata Esposito, Simona Dell’Aversana, Roberta Paolillo, Teresa Capovilla, Gloria Tamborini, Alessandro Alberto Nepitella, Pasquale Perrone Filardi & Piergiuseppe Agostoni. (2023) Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration. European Journal of Clinical Pharmacology 79:9, pages 1173-1184.
Crossref
Cinzia Nugara, Francesco Giallauria, Giuseppe Vitale, Silvia Sarullo, Giovanni Gentile, Francesco Clemenza, Annamaria Lo Voi, Antonino Zarcone, Elio Venturini, Gabriella Iannuzzo, Andrew JS Coats & Filippo M Sarullo. (2023) Effects of Sacubitril/Valsartan on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction and the Role of Percentage of Delayed Enhancement Measured by Cardiac Magnetic Resonance in Predicting Therapeutic Response: A Multicentre Study. Cardiac Failure Review 9.
Crossref
Hanna Fröhlich, Norbert Frey, Bent Estler, Mirjam Mäck, Philipp Schlegel, Jan Beckendorf, Lutz Frankenstein & Tobias Täger. (2022) Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure. American Journal of Cardiovascular Drugs 22:6, pages 695-704.
Crossref
José I. Morgado García-Polavieja, Andrea Sigismondi, Samuel Ortiz Cruces, Elena Gálvez Ríos, José Raúl López Aguilar, Ana J. Manovel Sánchez, Ana López Suárez & José Francisco Díaz Fernández. (2022) Impact of sacubitril/valsartan on the indication for defibrillator and left ventricular remodeling: real life data. REC: CardioClinics 57:3, pages 172-181.
Crossref
Francesco Orso, Andrea Herbst, Alessandra Pratesi, Francesco Fattirolli, Andrea Ungar, NiccolÒ Marchionni & Samuele Baldasseroni. (2022) New Drugs for Heart Failure: What is the Evidence in Older Patients?. Journal of Cardiac Failure 28:2, pages 316-329.
Crossref
Stefano Giovinazzo, Luca Carmisciano, Matteo Toma, Stefano Benenati, Daniela Tomasoni, Maria Pia Sormani, Italo Porto, Marco Canepa, Michele Senni, Marco Metra & Pietro Ameri. (2021) Sacubitril/valsartan in real‐life European patients with heart failure and reduced ejection fraction: a systematic review and meta‐analysis. ESC Heart Failure 8:5, pages 3547-3556.
Crossref
Marcelo Rodrigues dos Santos, Maria-Janieire de Nazaré Nunes Alves, Camila Paixão Jordão, Caio Eduardo Novaes Pinto, Kelly Thayane Souza Correa, Francis Ribeiro de Souza, Guilherme Wesley Peixoto da Fonseca, Joaquim Tomaz Filho, Marcel Costa, Rosa Maria Rodrigues Pereira, Carlos Eduardo Negrão & Antônio Carlos Pereira Barretto. (2021) Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study. American Heart Journal 239, pages 1-10.
Crossref
Clare Proudfoot, Rachel Studer, Tanvi Rajput, Ramandeep Jindal, Rumjhum Agrawal, Stefano Corda & Michele Senni. (2021) Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review. International Journal of Cardiology 331, pages 164-171.
Crossref
Sam Straw, Melanie McGinlay & Klaus K Witte. (2021) Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart 8:1, pages e001585.
Crossref
Giuseppe Vergaro, Paolo Sciarrone, Concetta Prontera, Silvia Masotti, Veronica Musetti, Alessandro Valleggi, Alberto Giannoni, Michele Senni, Michele Emdin & Claudio Passino. (2020) Renin profiling predicts neurohormonal response to sacubitril/valsartan. ESC Heart Failure 8:1, pages 719-724.
Crossref
Pedro Schwartzmann. (2020) Terapia com o Inibidor da Neprilisina e do Receptor de Angiotensina e Melhora de Parâmetros de Exercício na Insuficiência Cardíaca com Fração de Ejeção Reduzida. Arquivos Brasileiros de Cardiologia 115:5, pages 828-829.
Crossref
Massimo Mapelli, Elisabetta Salvioni, Fabiana de Martino, Irene Mattavelli, Alice Bonomi, Valentina Sassi, Paola Gugliandolo, Carlo Vignati, Alessandra Magini, Sara Rovai, Stefania Paolillo & Piergiuseppe Agostoni. (2020) Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction. Journal of Cardiovascular Medicine 21:11, pages 882-888.
Crossref
George Chalikias & Dimitrios Tziakas. (2020) Angiotensin Receptor Neprilysin Inhibitors—2019 Update. Cardiovascular Drugs and Therapy 34:5, pages 707-722.
Crossref
Francesco Giallauria, Giuseppe Vitale, Mario Pacileo, Anna Di Lorenzo, Alessandro Oliviero, Francesco Passaro, Roberta Calce, Alessandro Parlato, Crescenzo Testa, Giuseppe D’Ambrosio, Giuseppe Romano, Francesco Clemenza, Silvia Sarullo, Elio Venturini, Marco Gentile, Cinzia Nugara, Gabriella Iannuzzo, Antonello D’Andrea, Carlo Vigorito & Filippo M. Sarullo. (2020) Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction. Journal of Clinical Medicine 9:6, pages 1897.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.